A Phase 1b/2 Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination with Nivolumab in Patients with an Advanced Metastatic Solid Tumor

Brief description of study

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). We will enrolling in the Phase II portion of the trial.


Clinical Study Identifier: s19-01154
ClinicalTrials.gov Identifier: NCT04042116
Principal Investigator: Bhavana Pothuri.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.